Microrna-based particle for the treatment of dysregulated immune response

Abstract

A method for treating or preventing sepsis in a subject in need is disclosed. The method includes administering miRNA-based particles to a subject in need, and observing extended survival of a subject suffering from sepsis and reduced organ dysfunction or failure caused by the condition. Each of the miRNA-based particles includes miR-193b-5p inhibitor, encapsulated in a lipid nanoparticle carrier. The method is for treating dysregulated immune response induced by the sepsis. The method can be for treating acute respiratory distress syndrome, preventing or treating neuroinflammation, preventing lung injury, and any combination thereof. The lipid nanoparticle carrier includes an ionizable cationic lipid positively charged in a formulation buffer, a sterol, a structural helper lipid, and a PEGylated-lipid. Alternatively, the lipid carrier can be a cell membrane derived nano-vesicle.

Dependencies are inferred from the claim text.